Semaglutide Hong Kong: Uses, Dosage, Side Effects & How to Get It (2026)

Semaglutide Is the Molecule Behind Ozempic — and One of the Most Significant Advances in Metabolic Medicine in Decades

Most people encounter semaglutide through its brand names. Ozempic was approved for type 2 diabetes. Wegovy, the higher-dose formulation, was approved specifically for chronic weight management. Both contain the same active molecule: semaglutide, a synthetic analogue of GLP-1 (glucagon-like peptide-1) that has reshaped how medicine approaches obesity.

In clinical trials, semaglutide produced weight loss averaging 15% of body weight over 68 weeks — meaningfully higher than any previously available non-surgical intervention. In patients with cardiovascular disease, it reduced the risk of major cardiovascular events by 20%. In type 2 diabetes, it improved blood sugar control, reduced HbA1c, and in some patients allowed reduction or elimination of other diabetes medications.

This guide explains what semaglutide is, how it works at a molecular level, what the dosing schedule looks like, what side effects patients commonly experience, and how to access it in Hong Kong in 2026.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic molecule that mimics the action of glucagon-like peptide-1, a hormone naturally released by the gut after eating. Its chemical structure is based on the naturally occurring GLP-1 hormone but modified in two ways:

• A fatty acid side chain is attached, which binds to albumin in the blood and dramatically extends its half-life from minutes (for natural GLP-1) to approximately one week. This is what makes once-weekly dosing possible.

• A modification at position 8 of the amino acid chain makes it resistant to the enzyme that breaks down natural GLP-1, further extending its duration of action.

The result is a molecule that produces a sustained GLP-1 signal at a level substantially higher than the body generates naturally, over a week-long period.

How Semaglutide Works for Weight Loss

GLP-1 receptors are found throughout the body — in the pancreas, gut, brain, heart, and liver. Activating them produces several effects simultaneously:

Appetite reduction: GLP-1 receptors in the hypothalamus (the brain region that regulates hunger) are activated by semaglutide. This produces a meaningful reduction in appetite and caloric intake — typically 20–35% fewer calories consumed — without requiring conscious restriction. Patients on semaglutide commonly describe simply not feeling hungry, and feeling full much more quickly when they do eat.

Slowed gastric emptying: Food moves from the stomach into the small intestine more slowly, which extends the feeling of fullness after meals and blunts post-meal blood sugar spikes.

Improved insulin response: Semaglutide stimulates insulin release from the pancreas in a glucose-dependent manner — meaning it only triggers insulin when blood sugar is elevated. It also reduces glucagon (a hormone that raises blood sugar), improving overall glucose regulation.

Direct fat metabolism effects: Research suggests semaglutide influences fat cell metabolism and may promote breakdown of stored fat, particularly in the liver and visceral (abdominal) fat deposits.

The combined effect — less food intake, better blood sugar regulation, and potential direct metabolic effects — produces significant weight loss in most patients who tolerate the medication.

Semaglutide Dosing Schedule Example

Semaglutide (as Ozempic) is administered as a once-weekly subcutaneous injection. The titration schedule is designed to build the dose gradually, minimising gastrointestinal side effects during the adjustment period:

Here's an example of the timeframes when starting treatment. Individual experiences will vary.

The titration pace can be adjusted by the treating doctor depending on tolerance. Some patients stay at 0.5mg if that dose produces sufficient effect with acceptable tolerability; others move to 2mg for maximum weight loss.

Injections are made into the subcutaneous tissue of the abdomen, thigh, or upper arm using the pre-filled Ozempic pen. Injection sites should be rotated between doses.

Clinical Trial Results: What Semaglutide Achieves

The STEP programme of clinical trials (Semaglutide Treatment Effect in People with Obesity) provides the most comprehensive evidence base for semaglutide in weight management:

STEP 1 (adults with obesity or overweight without diabetes, semaglutide 2.4mg): Average weight loss of 14.9% at 68 weeks, compared to 2.4% with placebo. 86% of participants achieved at least 5% weight loss; 70% achieved at least 10%.

STEP 2 (adults with obesity and type 2 diabetes, semaglutide 2.4mg): Average weight loss of 9.6% at 68 weeks. Significant reductions in HbA1c alongside weight loss.

SUSTAIN-6 (semaglutide for cardiovascular risk reduction): 26% reduction in major cardiovascular events, including non-fatal heart attack and stroke, in patients with type 2 diabetes and high cardiovascular risk.

The results from the SELECT trial (published 2023), using semaglutide in patients with cardiovascular disease but without diabetes, showed a 20% reduction in major cardiovascular events — extending the evidence base beyond purely metabolic outcomes.

Side Effects of Semaglutide

The most common side effects are gastrointestinal and typically occur during the dose escalation period:

• Nausea — the most frequently reported side effect, affecting most patients to some degree. Usually peaks in the first 2–4 weeks at any given dose and reduces significantly as the body adapts.

• Constipation — common, related to slowed gastric emptying. Managed with increased water intake, dietary fibre, and physical activity.

• Reduced appetite and early satiety — the intended effect, but can feel uncomfortable initially. Important to maintain protein intake and adequate nutrition even as food volume decreases.

• Diarrhoea or loose stools — less common than constipation, typically transient.

• Vomiting — less common, more likely with rapid dose escalation. Slowing the titration schedule usually resolves it.

• Fatigue — often related to reduced caloric intake rather than the medication directly. IV nutritional support can help during the adjustment period.

Serious but rare side effects include acute pancreatitis (if severe upper abdominal pain occurs, stop the medication and seek immediate medical attention), gallbladder disease, and hypersensitivity reactions. The medication should not be used in patients with a history of medullary thyroid carcinoma or MEN2 syndrome, though a causal relationship with thyroid cancer in humans has not been established from clinical data.

Semaglutide vs Tirzepatide: The Key Difference

Semaglutide (Ozempic/Wegovy) activates the GLP-1 receptor. Tirzepatide (Mounjaro) activates both the GLP-1 and GIP receptors simultaneously. Head-to-head trial data (SURPASS-2) and indirect comparisons consistently show higher average weight loss with tirzepatide — approximately 20–22% vs 15% at comparable programme durations.

The choice between the two depends on individual health history, goals, tolerability, and cost considerations. Both are available in Hong Kong, and the treating doctor will advise which is more appropriate at consultation.

Is Semaglutide Available in Hong Kong?

Yes. Ozempic (semaglutide 0.5mg, 1mg, 2mg) is registered in Hong Kong and available on prescription from registered medical practitioners. Wegovy (semaglutide 2.4mg, the weight management formulation) is not separately registered in Hong Kong as of 2026, but Ozempic at 1–2mg doses is used for the same purpose under medical guidance.

How to Access Semaglutide at REVIV

REVIV offers semaglutide (Ozempic) and tirzepatide (Mounjaro) as part of a structured, medically supervised weight management programme. The programme begins with a health assessment, and provides ongoing clinical oversight through the titration period and beyond.

Many patients supplement the GLP-1 programme with IV nutritional support, NAD+ infusions for energy, and peptide protocols for muscle preservation during weight loss. The clinical team advises on what combination makes sense for each patient's goals.

Location: 1st Floor, The Plaza, 21 D'Aguilar Street, Central, Hong Kong
Opening hours: Monday to Sunday, 10:00 AM – 7:00 PM
WhatsApp: +852 9867 9183

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.

• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016.

• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 2023.

• Drucker DJ. GLP-1 Physiology Informs the Pharmacotherapy of Obesity. New England Journal of Medicine, 2022.

• Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.

• Hong Kong Department of Health — Pharmacy and Poisons Ordinance: Prescription Drugs.

The material on this page is provided for informational purposes only and is not medical advice. Always consult your doctor before beginning any therapy programme. All therapies are subject to medical screening and doctor consultation to approve responsible treatment.